From GWAS to clinical utility in Parkinson's disease-Reference-Cited by-同舟云学术

From GWAS to clinical utility in Parkinson's disease

Published:2011-02 Issue:9766 Volume:377 Page:613-614
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Klein Christine,Ziegler Andreas

Publisher

Elsevier BV

Subject

General Medicine

Reference9 articles.

1. Genetic analysis of pathways to Parkinson disease;Hardy;Neuron,2010

2. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies;Lancet,2011

3. How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom;Sanderson;Genet Med,2005

4. The impact of genotype frequencies on the clinical validity of genomic profiling for predicting common chronic diseases;Janssens;Genet Med,2007

5. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers;Jakobsdottir;PLoS Genet,2009

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gene Prioritization in Parkinson's Disease Using Human Protein–Protein Interaction Network;Journal of Computational Biology;2020-11-01

2. Genetics of Parkinson disease;Neurogenetics, Part I;2018

3. Application of Next-generation Sequencing in Clinical Molecular Diagnostics;Brazilian Archives of Biology and Technology;2017

4. Association of LRRK2 R1628P variant with Parkinson’s disease in Ethnic Han-Chinese and subgroup population;Scientific Reports;2016-11-04

5. Frecuencia de polimorfismos de nucleótido único y haplotipos de alfa-sinucleína asociados con la enfermedad de Parkinson esporádica en población mexicana;Revista de Neurología;2016